Dr. Mark S. Hoffrichter is a Frederick, Maryland based Oral and Maxillofacial Surgeon who is specialized in Oral and Maxillofacial Surgery. He may accept the Medicare-approved amount. Patients may be billed for more than the Medicare deductible and coinsurance. His current practice location is 604 Solarex Ct, Suite 207, Frederick. Patients can reach him at 301-695-5755.
Dr. Mark S. Hoffrichter deals with the diagnosis, surgical and adjunctive treatment of diseases, injuries and defects involving both the functional and esthetic aspects of the hard and soft tissues of the oral and maxillofacial region.
Complete Profile:
Dr. Mark S. Hoffrichter speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Name:
Dr. Mark S. Hoffrichter
Specialization:
Oral and Maxillofacial Surgeon
Gender:
Male
Credentials:
D.D.S.
Accepts Medicare Assignment:
May Accept
Practice Address:
604 Solarex Ct, Suite 207, Frederick, Maryland, 21703-7005
Phone:
301-695-5755
Fax:
301-695-0550
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
PAC ID:
2062710601
Enrollment ID:
I20160414000374
NPI Number:
1285652339
NPI Enumeration Date:
17 Jul, 2006
NPI Last Update On:
08 Jul, 2007
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
604 Solarex Ct, Suite 207 Frederick, Maryland
Zip:
21703-7005
Phone Number:
301-695-5755
Fax Number:
301-695-0550
Patients can reach Dr. Mark S. Hoffrichter at 604 Solarex Ct, Suite 207, Frederick, Maryland or can call to book an appointment on 301-695-5755. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.